We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 478

Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think
  • King & Wood Mallesons
  • Australia
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18

European developments: to regulate or not to regulate - that is the question?
  • Clayton Utz
  • Australia
  • September 30 2009

Australian manufacturers and suppliers who export products to the EU should keep in mind that reforms across a number of fronts could have an impact on their business

Competition regulators continue their campaign against pharmaceutical companies
  • King & Wood Mallesons
  • Australia, USA
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year

Recent mergers approved in the pharmaceutical industry
  • Herbert Smith Freehills LLP
  • Australia
  • November 12 2009

The ACCC has announced that it will not oppose two proposed acquisitions in the pharmaceutical sector: the proposed acquisition of Wyeth Corp by Pfizer Inc, and the proposed acquisition of Merck & Co Inc by Schering-Plough Corporation

ACCC authorises potential cartel conduct by private health funds
  • King & Wood Mallesons
  • Australia
  • November 3 2011

On 25 August 2011, the ACCC issued a final determination granting authorisation for a management services agreement between two private health funds, the Reserve Bank Health Society and Lysaght Peoplecare Limited

ACCC joins NRM to Advanced Medical Institute proceedings, alleging unfair contract terms
  • King & Wood Mallesons
  • Australia
  • November 3 2011

On 7 September 2011, the ACCC announced that the Federal Court had granted orders to add NRM Corporation Pty Ltd and NRM Trading Pty Ltd as respondents in the ACCC’s existing case against Advanced Medical Institute for alleged unconscionable conduct

Managing your risks under global anti-corruption regimes
  • Piper Alderman
  • Australia, United Kingdom, USA
  • September 13 2012

Pharmaceutical and medical device companies operate in a stringent regulatory environment

Generic pharmaceuticals and competition law: the ACCC vs Pfizer proceedings
  • Corrs Chambers Westgarth
  • Australia
  • March 10 2014

The ACCC has commenced proceedings in the Federal Court against Pfizer Australia Pty Ltd (Pfizer) alleging that commercial offers made by Pfizer to

Australian court fines Baxter almost A$5 million for abuse of market power
  • Rajah & Tann Asia LLP
  • Australia
  • October 18 2010

On 26 August 2010, The Full Federal Court of Australia imposed a penalty of A$4,9 million on Baxter Healthcare Pty Limited (‘Baxter’)for violations of section 46 (taking advantage of market power) and section 47 (exclusive dealing) of the Trade Practices Act 1974 (‘TPA’

Penalties for unconscious breaches of the Trade Practices Act
  • PwC Australia
  • Australia
  • September 14 2010

On 27 August 2010, the Federal Court ordered Baxter Healthcare Pty Ltd (Baxter) to pay penalties of $4.9 million in respect of contraventions of sections 46(1)(c) and 47(1) of the Trade Practices Act (1974) (the TPA